The WHO's critical bacteria list: scientific response eight years after its implementation and development of an AI-based tool for its monitoring.

IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Frontiers in Pharmacology Pub Date : 2025-09-11 eCollection Date: 2025-01-01 DOI:10.3389/fphar.2025.1633382
Juan Eduardo Robledo Almonacid, Christian Lombardo, Mariana Romano, Agustina Quiroga, Paula Cambuli Bianchi, Mauricio Hualpa, Constanza Giai, Xiomara María A Oviedo, Ramiro Alejo Salgado Mansur, Mariana Guadalupe Vallejo, Cristián Andrés Quintero
{"title":"The WHO's critical bacteria list: scientific response eight years after its implementation and development of an AI-based tool for its monitoring.","authors":"Juan Eduardo Robledo Almonacid, Christian Lombardo, Mariana Romano, Agustina Quiroga, Paula Cambuli Bianchi, Mauricio Hualpa, Constanza Giai, Xiomara María A Oviedo, Ramiro Alejo Salgado Mansur, Mariana Guadalupe Vallejo, Cristián Andrés Quintero","doi":"10.3389/fphar.2025.1633382","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In 2017, the World Health Organization (WHO) issued a global alert identifying 12 bacteria in urgent need of new treatments.</p><p><strong>Main body: </strong>This study assesses the scientific community's response to this alert by analyzing original research publications using LLMzCor, an AI-based tool developed and validated by our group. To compare trends, we focused on publications from 5 years before and after the alert, specifically on three bacteria listed in the WHO alert, sorted by priority level: <i>Acinetobacter baumannii</i> (Critical), <i>Shigella</i> spp (High), and <i>Neisseria gonorrhoeae</i> (Medium) and three non-listed as controls (<i>Rickettsia</i> spp., <i>C. trachomatis</i>, and <i>C. difficile)</i>. Articles were classified into three categories: (i) identification of Resistant strains, (ii) development of New treatments, and (iii) Immunization strategies.</p><p><strong>Results: </strong>Although overall publications increased after the WHO alert, no statistically significant changes were found in the reports of Resistant strains over time. The development of New treatments for the listed bacteria showed a slight increase, between 2% and 10%. Furthermore, Immunization strategies remained relatively unchanged, with less than 2%. Meanwhile, LLMzCor demonstrated robust performance across categories, F1-scores ranging from 0.65 to 0.72 in key classifications, while recall peaked at 0.75, indicating a high capacity to identify relevant articles. These results support the model's reliability for large-scale automated classification of scientific abstracts.</p><p><strong>Conclusion: </strong>These findings, supported by LLMzCor, underscore the urgency of a stronger WHO alert and action plans to develop new strategies against bacterial resistance.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1633382"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461225/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2025.1633382","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In 2017, the World Health Organization (WHO) issued a global alert identifying 12 bacteria in urgent need of new treatments.

Main body: This study assesses the scientific community's response to this alert by analyzing original research publications using LLMzCor, an AI-based tool developed and validated by our group. To compare trends, we focused on publications from 5 years before and after the alert, specifically on three bacteria listed in the WHO alert, sorted by priority level: Acinetobacter baumannii (Critical), Shigella spp (High), and Neisseria gonorrhoeae (Medium) and three non-listed as controls (Rickettsia spp., C. trachomatis, and C. difficile). Articles were classified into three categories: (i) identification of Resistant strains, (ii) development of New treatments, and (iii) Immunization strategies.

Results: Although overall publications increased after the WHO alert, no statistically significant changes were found in the reports of Resistant strains over time. The development of New treatments for the listed bacteria showed a slight increase, between 2% and 10%. Furthermore, Immunization strategies remained relatively unchanged, with less than 2%. Meanwhile, LLMzCor demonstrated robust performance across categories, F1-scores ranging from 0.65 to 0.72 in key classifications, while recall peaked at 0.75, indicating a high capacity to identify relevant articles. These results support the model's reliability for large-scale automated classification of scientific abstracts.

Conclusion: These findings, supported by LLMzCor, underscore the urgency of a stronger WHO alert and action plans to develop new strategies against bacterial resistance.

世卫组织的关键细菌清单:在实施和开发基于人工智能的监测工具八年后的科学反应。
背景:2017年,世界卫生组织(WHO)发布了一项全球警报,确定了12种迫切需要新疗法的细菌。本研究通过使用LLMzCor分析原始研究出版物来评估科学界对这一警报的反应,LLMzCor是我们小组开发并验证的基于人工智能的工具。为了比较趋势,我们将重点放在警报前后5年的出版物上,特别是WHO警报中列出的三种细菌,按优先级别分类:鲍曼不运动杆菌(严重)、志贺氏菌(高)和淋病奈瑟菌(中等),以及三种未列为对照的细菌(立克次氏体、沙眼衣原体和艰难梭菌)。文章被分为三类:(i)耐药菌株的鉴定,(ii)新治疗方法的开发,以及(iii)免疫策略。结果:尽管在世卫组织发出警告后,总体出版物有所增加,但随着时间的推移,耐药菌株的报告没有发现统计学上显著的变化。对所列细菌的新治疗方法的开发略有增加,在2%至10%之间。此外,免疫战略保持相对不变,不到2%。同时,LLMzCor在各个类别中表现出强大的性能,关键分类的f1得分范围为0.65至0.72,而召回率最高为0.75,表明识别相关文章的能力很高。这些结果支持了该模型对科学摘要进行大规模自动分类的可靠性。结论:在LLMzCor的支持下,这些发现强调了世卫组织加强警报和行动计划以制定新的细菌耐药战略的紧迫性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信